Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

X is O;

Y is a bond[[,]] or C_{1-6} alkylene optionally substituted by C_{1-4} alkyl or phenyl~~, phenylene optionally substituted by halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy, or heterocyclylene optionally substituted by halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy~~;

Z is CO_2R^b, $NHS(O)_2CF_3$, $S(O)_2OH$, $OCH_2CO_2R^b$ or tetrazolyl;

R^1 is aryl;

R^2 is hydrogen, C_{1-6} alkyl, aryl or heterocyclyl;

R^a and R^b are, independently, hydrogen or C_{1-4} alkyl; or when R^2 is aryl or heterocyclyl R^a optionally is C_{2-3} alkylene forming a ring with an ortho position on R^2;

R^c is hydrogen or hydroxy;

wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, $S(O)_pR^4$, $OC(O)NR^5R^6$, NR^7R^8, $NR^9C(O)R^{10}$, $NR^{11}C(O)NR^{12}R^{13}$, $S(O)_2NR^{14}R^{15}$, $NR^{16}S(O)_2R^{17}$, $C(O)NR^{18}R^{19}$, $C(O)R^{20}$, CO_2R^{21}, $NR^{22}CO_2R^{23}$, C_{1-6} alkyl, CF_3, C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, OCF_3, C_{1-6} alkoxy(C_{1-6})alkoxy, C_{1-6} alkylthio, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl optionally substituted by C_{1-4} alkyl or oxo, methylenedioxy, difluoromethylenedioxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenyl(C_{1-4})alkoxy, heterocyclyl, heterocyclyl(C_{1-4})alkyl, heterocyclyloxy or

heterocyclyl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heterocyclyl moieties are optionally substituted with halogen, hydroxy, nitro, $S(O)_q(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3;

p and q are, independently, 0, 1 or 2;

R^3, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{18}, R^{19}, R^{20}, R^{21} and R^{22} are, independently, hydrogen, C_{1-6} alkyl optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl, $CH_2(C_{2-6}$ alkenyl), phenyl optionally substituted by halogen, hydroxy, nitro, NH_2, $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3) or heterocyclyl optionally substituted by halogen, hydroxy, nitro, NH_2, $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 below, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3;

alternatively NR^5R^6, NR^7R^8, $NR^{12}R^{13}$, $NR^{14}R^{15}$, $NR^{18}R^{19}$, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by C_{1-4} alkyl on the distal nitrogen;

R^4, R^{17} and R^{23} are, independently, C_{1-6} alkyl optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl, $CH_2(C_{2-6}$ alkenyl), phenyl itself optionally substituted by halogen, hydroxy, nitro, NH_2, $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as

described for R^5 and R^6 above, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl$)_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3) or heterocyclyl optionally substituted by halogen, hydroxy, nitro, NH_2, $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl$)_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl$)_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl$)_2$ and these alkyl groups optionally join to form a ring as described for R^5 and R^6 above, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3;

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

2. (Original) A compound as claimed in claim 1 wherein R^1 is phenyl optionally substituted with halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

3. (Cancelled)

4. (Previously Presented) A compound as claimed in claim 1 wherein R^a and R^c are both hydrogen.

5. (Previously Presented) A compound as claimed in claim 1 wherein Z is CO_2R^b.

6. (Previously Presented) A compound as claimed in claim 1 wherein Y is a bond or alkylene optionally substituted by C_{1-4} alkyl; R^a is hydrogen; and, R^2 is hydrogen, C_{1-6} alkyl, phenyl optionally substituted by halogen, C_{1-4} alkyl, C_{1-4} alkoxy or $NHC(O)(C_{1-4}$ alkyl) or heterocyclyl optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

7. (Cancelled)

8. (Previously Presented) A process for preparing a compound of formula (I) as claimed in claim 1, the process comprising:

a) coupling a compound of formula (II):



(II)

with a compound of formula (III):



(III)

wherein L is a suitable leaving group;

b) when R^a is hydrogen and Z is CO_2R^b, reductive amination of a compound (II) with a compound of formula (IV):



(IV)

wherein R^b is C_{1-4} alkyl, in the presence of $NaBH(OAc)_3$ and acetic acid, or $NaBH_3CN$ in a suitable solvent, optionally followed by hydrolysis of the ester group;

c) when Y is a bond, R^a and R^b are both hydrogen and Z is CO_2H, a three component coupling of a compound of formula (II) with compounds of formula (V) and (VI):



(V)



(VI)

in a suitable solvent at a suitable elevated temperature;

d) when Y is a bond and Z is CO_2H, performing a nitrile hydrolysis on a compound of formula (XI):



(XI)

e) when Z is tetrazol-5-yl, reacting a compound of formula (XI) with $(CH_3)_3SiN_3$ and $(Bu_3Sn)_2O$ at an elevated temperature;

f) when Z is $NHS(O)_2CF_3$, reacting a compound of formula (XII):



(XII)

with triflic anhydride at a reduced temperature.

9. (Original) A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

10-11. (Cancelled)

12. (Withdrawn) A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.

13-14. (Cancelled)